{
  "main_header": {
    "sid": 657348,
    "name": "Aarti Drugs",
    "stock_name": "Aarti Drugs",
    "full_name": "Aarti Drugs Ltd",
    "name_url": "stocks-analysis/aarti-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "441.00",
    "chg": 19.65,
    "chgp": "4.66%",
    "dir": 1,
    "prev_price": "421.35",
    "mcapval": "3,878.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 524348,
    "symbol": "AARTIDRUGS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE767A01016",
    "curr_date": "Aug 11",
    "curr_time": "",
    "bse_nse_vol": "13.66 lacs",
    "exc_status": "Active",
    "traded_date": "Aug 11, 2026",
    "traded_date_str": "2026 08 11",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/aarti-drugs-657348-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Aarti Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/aarti-drugs-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-challenges-3997764",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AartiDrugsLtd_valuationdot_3997764.png",
        "date": "2026-05-19 08:01:13",
        "description": "Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks."
      }
    ],
    "total": 15,
    "sid": "657348",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/aarti-drugs-657348"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Earnings Call Transcript",
      "datetime": "07-Aug-2026",
      "details": "Q1FY27 Earning call transcript",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "04-Aug-2026",
      "details": "Intimation of Analyst /Institutional Investors Meeting",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "03-Aug-2026",
      "details": "Newspaper Publication on Financial results",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has declared <strong>20%</strong> dividend, ex-date: 09 Feb 26",
          "dt": "2026-02-09",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Aarti Drugs Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 30 Sep 20",
          "dt": "2020-09-30",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Aarti Drugs Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Challenges

2026-05-19 08:01:13

Aarti Drugs Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, reflecting a more compelling price proposition for investors within the Pharmaceuticals & Biotechnology sector. Despite recent market headwinds and a modest decline in share price, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a more favourable entry point relative to historical averages and peer benchmarks.

Read More

View All News